Mapatumumab

• Description :

  Mapatumumab (HGS-ETR1) is a fully human IgG1 agonistic monoclonal antibody that targets tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) . Mapatumumab can be used for the research of cancer[1].

• Product Name Alternative :

  HGS-ETR1; Anti-Human TNFRSF10A Recombinant Antibody

• UNSPSC :

  12352203

• Target :

  Others

• Type :

  Inhibitory Antibodies

• Related Pathways :

  Others

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/mapatumumab.html

• Purity :

  97.85

• Solubility :

  10 mM in DMSO

• Smiles :

  [Mapatumumab]

• Molecular Weight :

  (143.52 kDa)

• References & Citations :

  [1]Smith MA, et al. Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program. Pediatr Blood Cancer. 2010 Feb;54 (2) :307-10.|[2]Ahmed SM, et al. Synergistic induction of apoptosis by mapatumumab and anthracyclines in human bladder cancer cells. Oncol Rep. 2015 Feb;33 (2) :566-72.|[3]Marini P, et al. Combination of the pro-apoptotic TRAIL-receptor antibody mapatumumab with ionizing radiation strongly increases long-term tumor control under ambient and hypoxic conditions. Int J Radiat Oncol Biol Phys. 2009 Sep 1;75 (1) :198-202.

• Shipping Conditions :

  Dry Ice

• Storage Conditions :

  Store at -80°C for 2 years

• Scientific Category :

  Inhibitory Antibodies

• Clinical Information :

  Phase 2

• CAS Number :

  [658052-09-6]